Navigation Links
Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research

EMERYVILLE, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present findings on the mechanism of action of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical testing for late stage breast cancer at the American Association of Cancer Research (AACR) being held at the Los Angeles Convention Center in Los Angeles, CA, April 14 - 17, 2007.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BZL101 while leaving normal cells unaffected. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BZL101 to induce apoptosis is due to attenuation of mitochondrial transmembrane potential (MTP) leading to the release of reactive oxygen species, causing inhibition of glycolysis and ending with induction of oxidative DNA damage.

A paper on BZL101's mechanism of action and unique selective properties based on the company's initial Phase 1 clinical trial was published late last year in the peer-reviewed journal, Breast Cancer Research and Treatment.

"BZL101's mechanism of action and unique selective properties" said Dr. Isaac Cohen, President and CEO of Bionovo, "are a result of some of the biological differences between cancer cells and normal cells. We are hoping that capitalizing on the difference will result in a safe and effective treatment for cancer."

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 4 drug candidates expected to be in clinical trials by the end of 2007. The company is developing its products in close collaboration with leading U.S. academic research centers, including the University of California, San Francisco, University of Colorado Health Sciences Center and University of California, Berkeley. For further information please visit: http://www.bionovo.com.

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

CONTACT: Jim Stapleton, Chief Financial Officer, +1-510-420-4180,; media, Katherina Audley, +1-415-847-7295,, both of BioNovo jim@bionovo.com Katherina.audley@bionovo.com

Web site: http://www.bionovo.com/

Ticker Symbol: (NASDAQ-OTCBB:BNVI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Insight 2022" drug pipelines to their offering. ... Global Immune ... gives comprehensive insight on clinical and non-clinical aspects involved in ... main streamline drugs in the immunotherapy treatment. Report helps to ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The ... of around 7.1% over the next decade to reach approximately $129.81 ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... On 2 March 2017, the United ... Operations Command’s Patriot Award. The award was presented by the USSOCOM Commander, General ... for its significant and enduring support to the command. , Accepting the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change the ...
(Date:3/23/2017)... Las Vegas, Nevada (PRWEB) , ... March 23, 2017 , ... ... March 25th from 10am - 2pm. All events will be located in the ... will be hosting a no-cost Child ID event. No appointment is necessary and each ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, testimony ... Europe for public health and the environment and is calling on the United States ... the overwhelming support of European citizens, the European Union (EU) will, beginning next year, ...
Breaking Medicine News(10 mins):